International Pharmaceutical Regulators Forum (IPRF)
The European Medicines Agency (EMA) participates in the International Pharmaceutical Regulators Forum (IPRF). IPRF aims to create an environment for pharmaceutical regulators to exchange of information on issues of mutual concern and regulatory cooperation.
Merger of IPRF and the International Generic Drug Regulators Programme (IGDRP) (new)
IPRF and IGDRP have merged to form a single forum for international regulators to exchange practice and develop opportunities for cooperation, the International Pharmaceutical Regulators Programme (IPRP).
This new forum was launched on 1 January 2018. IPRP expects to launch a new website in the second quarter of 2018. For more information, see the press release by IPRF.
The main goals include:
- enabling all parties to identify new approaches and best practices, and develop smart strategies for dealing with the challenges of a rapidly evolving globalised pharmaceutical industry;
- providing a global overview of different regulatory developments at national and international level and enabling the sharing of information and ideas among regulatory leaders with hands-on operational responsibilities. This allows members to discuss issues at an actionable level of detail;
- supporting international regulatory cooperation in areas not covered by other initiatives.
EMA participates in IPRF as:
- member of its management committee;
- leader of the nanomedicines working group.
- member of the biosimilars working group;
- rotating chair of the gene therapy working group and cell therapy working group.
EMA also informs IPRF members about the workshops and training courses organised at EMA or delivered via the EU Network Training Centre (EU NTC).